In alcuni casi di recidiva si possono colpire mutazioni geniche
Search Results for: Le cure a domicilio: Chi curare, cosa fare e cosa non fare
Here's what we've found for you
Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg)
Background
Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating Helicobacter pylori infection even in areas of high bacterial antibiotic resistance.
Objective
To describe the time trends of use, effectiveness and safety of BQT in Europe using the European Registry on Helicobacter pylori Management (Hp-EuReg).
Design
Patients registered in the Hp-EuReg from 2013 to 2021 who had received BQT were included. The regimens prescribed, the number of eradication attempts, effectiveness, adherence and safety were analysed. The effectiveness was assessed by modified intention to treat (mITT). Time-trend and multivariate analyses were performed to determine variables that predicted treatment success.
Results
Of the 49 690 patients included in the Hp-EuReg, 15 582 (31%) had received BQT. BQT use increased from 8.6% of all treatments in 2013 to 39% in 2021. Single-capsule BQT—containing bismuth, metronidazole and tetracycline—plus a PPI (single-capsule BQT, ScBQT) was the most frequent treatment mode (43%). Schemes that obtained an effectiveness above 90% were the 10-day ScBQT and 14-day BQT using tetracycline plus metronidazole, or amoxicillin plus either clarithromycin or metronidazole. Only ScBQT achieved above 90% cure rates in all the geographical areas studied. Using the ScBQT scheme, adherence, the use of standard or high-dose PPIs, 14-day prescriptions and the use of BQT as first-line treatment were significantly associated with higher mITT effectiveness.
Conclusion
The use of BQT increased notably in Europe over the study period. A 10-day ScBQT was the scheme that most consistently achieved optimal effectiveness.
Trial registration number
NCT02328131.
Maculopatia senile, nuove cure grazie alla terapia genica
Stabilizza vista e può ridurre necessità iniezioni intravitreali
Ictus e demenze, accordo San Raffaele-Univ.Shanghai sulla ricerca per nuove cure riabilitative
Impegno per scambio di dati e studi per il recupero pazienti
Autismo: 5mila casi all'anno, ma le nuove terapie ancora una volta escluse dalle cure gratuite
In Italia una legislazione molto avanzata, ma applicata male a livello regionale
Melanoma, terapia con virus modificato per i casi difficili
Efficace nel 30% dei pazienti che non risponde alle altre cure
Stool Metabolites Could Aid in Endometriosis Diagnosis and Therapy
Women with endometriosis—a painful condition with no cure that is a leading cause of infertility—have distinct stool metabolites that could be used for noninvasive diagnoses, according to research recently published in Med. A metabolite that is reduced in these women, meanwhile, has implications for treatment, the authors reported.
L'Aids uccide 250 under 14 ogni giorno, a rischio ragazze
Bilancio Giornata mondiale, ancora 1 su 4 non ha accesso a cure
Riccardi, “Carta di Udine” nasce attorno alla persona
Assessore intervenuto a “Stati generali per umanizzazione cure”
Nasce la Carta di Udine per l'umanizzazione delle cure
Stati generali aderiscono anche al Manifesto “Dignitas Curae”
Mattarella, serve una spinta vigorosa per le cure palliative
Non del tutto attuate e disomogenee, trasmetterò tema al governo
Linee guida neoplasia della mammella
Le Linee Guida AIOM Neoplasie della Mammella hanno lo scopo […]
Linee Guida Neoplasie Cerebrali
Le Linee guida AIOM sulle neoplasie cerebrali hanno lo scopo […]
Linee guida EAN sulla gestione della sclerosi laterale amiotrofica (SLA)
Il seguente aggiornamento delle Linee Guida sulla gestione della sclerosi […]
La fuga dei pazienti al Nord costa 3 miliardi, in manovra la spinta alle cure sotto casa
Il fenomeno della cosiddetta mobilità sanitaria è legato alle differenze nell’offerta dell’assistenza sanitaria tra le Regioni
Alzheimer, speranze da uno spray nasale dopo test su animali
Univ. Cattolica, svelato nuovo bersaglio cure